- Previous Close
2.6300 - Open
2.5600 - Bid 1.8200 x 200
- Ask 3.0900 x 200
- Day's Range
2.4000 - 2.6289 - 52 Week Range
2.3100 - 17.6470 - Volume
197,355 - Avg. Volume
174,731 - Market Cap (intraday)
77.059M - Beta (5Y Monthly) 1.71
- PE Ratio (TTM)
4.79 - EPS (TTM)
0.5300 - Earnings Date Mar 19, 2025 - Mar 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.79
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
skyebioscience.comRecent News: SKYE
View More
Performance Overview: SKYE
Trailing total returns as of 3/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SKYE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SKYE
View MoreValuation Measures
Market Cap
79.79M
Enterprise Value
12.57M
Trailing P/E
4.96
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.05
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.39%
Return on Equity (ttm)
-54.82%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.24M
Diluted EPS (ttm)
0.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
67.41M
Total Debt/Equity (mrq)
0.25%
Levered Free Cash Flow (ttm)
-15.71M
Research Analysis: SKYE
View MoreCompany Insights: SKYE
SKYE does not have Company Insights